PD-1: A critical player and target for immune normalization.
Immunology
; 172(2): 181-197, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38269617
ABSTRACT
Immune system imbalances contribute to the pathogenesis of several different diseases, and immunotherapy shows great therapeutic efficacy against tumours and infectious diseases with immune-mediated derivations. In recent years, molecules targeting the programmed cell death protein 1 (PD-1) immune checkpoint have attracted much attention, and related signalling pathways have been studied clearly. At present, several inhibitors and antibodies targeting PD-1 have been utilized as anti-tumour therapies. However, increasing evidence indicates that PD-1 blockade also has different degrees of adverse side effects, and these new explorations into the therapeutic safety of PD-1 inhibitors contribute to the emerging concept that immune normalization, rather than immune enhancement, is the ultimate goal of disease treatment. In this review, we summarize recent advancements in PD-1 research with regard to immune normalization and targeted therapy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Receptor de Muerte Celular Programada 1
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article